Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Pomalidomide Bortezomib And Dexamethasone For Multiple Myeloma Previously Treated With Lenalidomide Optimismm Outcomes By Prior Treatment At First Relapse
Download Pomalidomide Bortezomib And Dexamethasone For Multiple Myeloma Previously Treated With Lenalidomide Optimismm Outcomes By Prior Treatment At First Relapse full books in PDF, epub, and Kindle. Read online Pomalidomide Bortezomib And Dexamethasone For Multiple Myeloma Previously Treated With Lenalidomide Optimismm Outcomes By Prior Treatment At First Relapse ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Pomalidomide, Bortezomib, and Dexamethasone for Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): Outcomes by Prior Treatment at First Relapse by : Meletios A. Dimopoulos
Download or read book Pomalidomide, Bortezomib, and Dexamethasone for Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): Outcomes by Prior Treatment at First Relapse written by Meletios A. Dimopoulos and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Abstract: In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse (N = 226) by lenalidomide-refractory status, prior bortezomib exposure, and prior stem cell transplant (SCT). Second-line PVd significantly improved PFS vs Vd in lenalidomide-refractory (17.8 vs 9.5 months; P = 0.0276) and lenalidomide-nonrefractory patients (22.0 vs 12.0 months; P = 0.0491), patients with prior bortezomib (17.8 vs 12.0 months; P = 0.0068), and patients with (22.0 vs 13.8 months; P = 0.0241) or without (16.5 vs 9.5 months; P = 0.0454) prior SCT. In patients without prior bortezomib, median PFS was 20.7 vs 9.5 months (P = 0.1055). Significant improvement in overall response rate was also observed with PVd vs Vd in lenalidomide-refractory (85.9% vs 50.8%; P
Book Synopsis Novel Agents for Multiple Myeloma by : Claudio Cerchione
Download or read book Novel Agents for Multiple Myeloma written by Claudio Cerchione and published by Frontiers Media SA. This book was released on 2024-05-07 with total page 180 pages. Available in PDF, EPUB and Kindle. Book excerpt: Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. It accounts for approximately 1.8% of all hematologic and solid cancers and slightly > 15% of hematologic malignancies in the United States. MM is typically sensitive to different classes of cytotoxic drugs, both as frontline treatment and as treatment for relapsed disease. Unfortunately, even if responses are typically durable, nowadays MM is not considered curable with current approaches. However, MM survival rates have been brilliantly improved thanks to the introduction of novel agents: patients diagnosed after 2010 have had higher rates of novel therapy use and better survival outcomes compared with those of earlier years. Most relevant therapeutic advances over the past decades has been the introduction of novel therapies, such as immune-modifying agents (thalidomide and lenalidomide) and proteasome inhibitors (bortezomib), adopted with or without stem cell transplantation.
Book Synopsis Small Molecules in Hematology by : Uwe M. Martens
Download or read book Small Molecules in Hematology written by Uwe M. Martens and published by Springer. This book was released on 2018-08-01 with total page 297 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title.
Book Synopsis FDA's Drug Review Process and the Package Label by : Tom Brody
Download or read book FDA's Drug Review Process and the Package Label written by Tom Brody and published by Academic Press. This book was released on 2017-12-01 with total page 671 pages. Available in PDF, EPUB and Kindle. Book excerpt: FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug
Book Synopsis The Bethesda Handbook of Clinical Oncology by : Jame Abraham
Download or read book The Bethesda Handbook of Clinical Oncology written by Jame Abraham and published by Lippincott Williams & Wilkins. This book was released on 2022-07-14 with total page 1046 pages. Available in PDF, EPUB and Kindle. Book excerpt: Offering up-to-date, authoritative information in a quick-reference format, The Bethesda Handbook of Clinical Oncology, Sixth Edition, is a comprehensive yet concise review of the management of different cancer types. Drs. Jame Abraham, James L. Gulley, and a team of expert contributors emphasize practical information that can be applied in everyday patient care situations, and thoroughly revised content keeps you current with advances in this fast-changing field.
Book Synopsis Elsevier's 2022 Intravenous Medications - E-Book by : Shelly Rainforth Collins
Download or read book Elsevier's 2022 Intravenous Medications - E-Book written by Shelly Rainforth Collins and published by Elsevier Health Sciences. This book was released on 2021-04-16 with total page 1408 pages. Available in PDF, EPUB and Kindle. Book excerpt: Find the essential information you need to safely administer more than 400 intravenous drugs! For more than 45 years, Gahart’s Intravenous Medications: A Handbook for Nurses and Health Professionals has been a trusted resource for comprehensive drug coverage, unparalleled accuracy, and an intuitive quick-access format. In addition to updated drug interactions, precautions, alerts, and patient teaching instructions for all existing IV drugs, the 2022 edition includes approximately 10 new monographs of the most recent IV drugs to be approved by the FDA. Administering intravenous drugs is a critical task — inaccurate or out-of-date information is not an option. Known as the #1 IV drug handbook on the market, and with its history of impeccable accuracy, Gahart’s annual publication gives you the extra confidence and guidance you need to safely and effectively treat patients. Monographs on more than 400 IV drugs offer an impressive breadth of coverage that goes well beyond any comparable drug reference. Updated annual publication prevents you from referencing outdated information. Additional drug monographs are provided on the companion Evolve website. 45-year history of impeccable accuracy reinforces the importance of safe IV drug administration. Perfect depth of information equips you with everything that is needed for safe administration of IV drugs — nothing more, nothing less. Proven, clinically optimized format keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. Special circumstances in blue-screened text call attention to important circumstances that may not warrant Black Box Warnings. Life-stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients. Dilution and dosage charts within monographs provide quick access to essential clinical information. Convenient, alphabetical format organizes all drug monographs by generic name, allowing you to find any drug in seconds. NEW! Drug monographs for newly approved drugs by the FDA provide you with the most current drug information. Updates on drug interactions, precautions, alerts, and more have been made throughout the guide to reflect all changes to existing medications.
Book Synopsis Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM) by : Martha Q. Lacy
Download or read book Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM) written by Martha Q. Lacy and published by . This book was released on 2014 with total page 4 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Pomalidomide-Dexamethasone In The Management Of Heavily Pretreated Multiple Myeloma by : Cerchione Claudio
Download or read book Pomalidomide-Dexamethasone In The Management Of Heavily Pretreated Multiple Myeloma written by Cerchione Claudio and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: POMALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF HEAVILY PRETREATED MULTIPLE MYELOMAAuthors: C. Cerchione, D. Nappi, A. E. Pareto, I. Migliaccio, I. Zacheo, M. Di Perna, I. Peluso, K. Ferrara, F. Pane, L. CatalanoCONTEXT: Pomalidomide-Dexamethasone is effective in heavily pretreated Multiple Myeloma OBJECTIVE : Pomalidomide is a new generation IMID, with a very good compliance, thanks to oral administration, which can be used also in heavily pretreated patients, in a domestic setting.DESIGN: In this retrospective observational trial, It has been evaluated efficacy and tolerance of pomalidomide plus dexamethasone (PD) as salvage regimen in heavily pretreated patients with relapsed and refractory MM (rrMM), whose prognosis is particularly severe. SETTING : Relapsed and Refractory Multiple Myeloma PATIENTS OR OTHER PARTICIPANTS : 29 patients (17 M/12 F), with rrMM, median age at diagnosis 69 years (r. 52-84), and median age at start of treatment 76 years (r.56-89) treated with several lines of treatments (median 7, r. 2-11), every refractory to all the drugs previously received (also Bortezomib, Thalidomide and Lenalidomide), received Pomalidomide-Dexamethasone (Pomalidomide 4 mg for 21 days, Dexamethasone 40 mg days 1,8,15,22, pegfilgrastim day +8) every 28 days, until progression.ISS was equally distributed, and cytogenetic was evaluable in 14 patients, and in particular three del13q and one t(11;14) were present. All the patients had previously been treated with schedule containing bortezomib and IMIDs. 55% (16/29) of them had undergone at least to a single ASCT. All patients were relapsed and refractory to last therapies received before PD.RESULTS: Pomalidomide was well tolerated, with grade 3 anemia in 48% (14/29) of patients, 31% (9/29) grade 3 neutropenia (pegfilgrastim in primary prophylaxis was given, no hospitalization was required, no septic shocks were observed), 27% (8/29) grade 3-4 thrombocytopenia without hemorrhagic events and transfusion-dependence. No severe extra-hematologic toxicity was observed.According to IMWG, ORR1 (u2265PR) was 44% (13/29: 3 CR, 4 VGPR, 6 PR), but, considering that we are evaluating a cohort of heavily pretreated patients without any other alternative treatment, with really poor prognosis, another parameter should be considered, ORR2 (u2265SD), considering stable disease as a successful result in progressive MM. ORR2 was 76% (22/29: 3 CR, 4 VGPR, 6 PR, 8 SD). These can be considered as impressive result in this subset of patients.Oral treatment gives a really good compliance, in frail and unfit patients, and response, when present, is always really fast (median time to response: 2 months (r.1-6)), median OS from diagnosis was 92 months (range 21-228), median OS from start of pomalidomide was 8 months (range 1-18).CONCLUSIONS: Pomalidomide-dexamethasone has shown significant efficacy and a very good compliance, thanks to oral administration, in a particularly severe setting of heavily pretreated patients, relapsed and refractory to all available therapeutic resources.
Book Synopsis Onco-Nephrology E-Book by : Kevin W. Finkel
Download or read book Onco-Nephrology E-Book written by Kevin W. Finkel and published by Elsevier Health Sciences. This book was released on 2019-07-02 with total page 498 pages. Available in PDF, EPUB and Kindle. Book excerpt: Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed. - Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy. - Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer. - Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment. - Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care. - Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies – treatments that are being recognized for adverse kidney effects. - Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
Download or read book Hematology written by Ronald Hoffman and published by Elsevier Health Sciences. This book was released on 2022-10-27 with total page 2886 pages. Available in PDF, EPUB and Kindle. Book excerpt: Extensively revised, comprehensive content from leading global contributors ensures that Hematology, 8th Edition, remains your #1 choice for expert guidance in all areas of this rapidly advancing subspecialty. This edition reflects the numerous advances that are redefining the field and dramatically influencing new approaches to diagnosis, treatment, and outcomes. Well-illustrated and clinically focused, it details the basic science and clinical practice of hematology and hematopoietic cellular therapy—covering virtually all aspects of hematology in one definitive resource. Covers all hematologic disorders, including comprehensive discussions of hematologic malignancies, individualized patient care, cell-based therapies, transplantation, transfusion medicine, hemostasis, thrombosis, and consultative hematology—in one convenient volume. Provides state-of-the-art guidance from global experts at the forefront of the latest research and clinical practice. Provides extensive updates throughout on basic science research, advances in molecular diagnostics, new drugs, immunotherapies, personalized medicine, laboratory medicine, transfusion medicine, stem cell transplantation, and clinical treatment for all hematologic malignancies and non-malignancies Contains new chapters on gene editing; the impact of mitochondria on hematopoiesis; myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes; immunotherapy and management of its toxicities; transfusion medicine in sickle cell disease; principles of radiation therapy; and COVID-19, including complications of vaccination and its impact on the hematologic system. Discusses many new advances in the field, including details and the future of gene therapy for hemophilia, gene editing for sickle cell disease and thalassemia, the evolution of cellular therapy, use of cells, transfusion medicine vs. protein therapy, gene sequencing, immunotherapy, and new targeted drugs. Includes more decision-making algorithms for formulating diagnoses and personalized treatment plans for those highly complex disorders that require individualized approaches. Addresses the effects of aging on hematopoiesis and on the manifestations of a variety of hematologic disorders. Discusses cardio-oncology and its impact on the treatment of patients with hematologic disorders. Presents relevant basic science as background for clinical application in later sections.
Book Synopsis Marine Compounds and Cancer by : Friedemann Honecker
Download or read book Marine Compounds and Cancer written by Friedemann Honecker and published by MDPI. This book was released on 2018-06-26 with total page 119 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a printed edition of the Special Issue "Marine Compounds and Cancer" that was published in Marine Drugs
Book Synopsis Successful Drug Discovery, Volume 1 by : János Fischer
Download or read book Successful Drug Discovery, Volume 1 written by János Fischer and published by John Wiley & Sons. This book was released on 2015-05-04 with total page 258 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first volume of the book series "Successful Drug Discovery" is focusing on new drug discoveries during the last decade, from established drugs to recently introduced drugs of all kinds: small-molecule-, peptide-, and protein-based drugs. The role of serendipity is analyzed in some very successful drugs where the research targets of the lead molecule and the drug are different. Phenotypic and target-based drug discovery approaches are discussed from the viewpoint of pioneer drugs and analogues. This volume gives an excellent overview of insulin analogues including a discussion of the properties of rapid-acting and long-acting formulations of this important hormone. The major part of the book is devoted to case histories of new drug discoveries described by their key inventors. Eight case histories range across many therapeutic fields. The goal of this book series is to help the participants of the drug research community with a reference book series and to support teaching in medicinal chemistry with case histories and review articles of new drugs.
Book Synopsis Carfilzomib-Lenalidomide-Dexamethasone In The Management Of Lenalidomide-Refractory Multiple Myeloma by : Cerchione Claudio
Download or read book Carfilzomib-Lenalidomide-Dexamethasone In The Management Of Lenalidomide-Refractory Multiple Myeloma written by Cerchione Claudio and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Title: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE IN THE MANAGEMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMAAuthors: C. Cerchione, K. Ferrara, I. Peluso, M. Di Perna, I. Zacheo, D. Nappi, A. E. Pareto, F. Pane, L. CatalanoCONTEXT: Carfilzomib-Lenalidomide-Dexamethasone is effective in heavily pretreated Multiple Myeloma, refractory to lenalidomideOBJECTIVE: Carfilzomib is an epoxyketone proteasome inhibitor of second generation, proved to be effective and safe in relapsed and refractory Multiple Myeloma (rrMM), in combination with dexamethasone or lenalidomide and dexamethasone.DESIGN: In this retrospective observational trial, it has been evaluated efficacy and safety of carfilzomib, in combination with lenalidomide-dexamethasone (KRD) as salvage regimen in patients with rrMM, refractory to lenalidomide, whose prognosis is particularly severe.SETTING : Relapsed and Refractory Multiple MyelomaPATIENTS OR OTHER PARTICIPANTS: 31 patients (19 M/12 F), with rrMM, median age at diagnosis 64 years (r. 47-82), median age at start of treatment 68 years (r. 48-84) previously treated with several lines of treatments (median 3, r. 2-11), underwent to KRD regimen (ASPIRE trial schedule) for a median treatment cycles of 4 (r 1-14).ISS was equally distributed, and cytogenetic was evaluable in 8 patients, and in particular one del13q14 1q gain, one del13q14 and one t(11;14). All patients had previously been treated with bortezomib and IMIDs, and were refractory to this agents. 61% (19/31) of them had undergone at least to a single autologous SCT.RESULTS: According to IMWG criteria, after a median follow-up of 3 months (r.1-13), ORR was 67,7% (21/31: 5 CR, 9 VGPR, 7 PR) with 4 progressive diseases (PD) and 6 patients in stable disease (SD): this can be considered as an impressive result in this subset of rrMM patients, refractory to lenalidomide. In particular, for 2 patients, KRD was, after having achieved at least a PR, a bridge to second autologous SCT.Median time to response was 2 months (r.1-4), median OS from diagnosis was 57 months (r. 9-170), median OS from start of Carfilzomib was 6 months (r. 1-14).Carfilzomib was well tolerated, with grade 2 anemia in 35% (11/31) of patients, successfully managed by ESAs, without necessity of blood transfusions; 19% (6/31) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis was given, no ospedalization was required, no septic shocks were observed); 32% (10/31) grade 2, 19% (6/31) grade 3 and 9% (3/31) grade 4 thrombocytopenia, without hemorrhagic events and necessity of transfusions. Concerning severe extra-hematologic toxicity, it was observed pneumonia in 45% (14/31) of patients, treated by common antibiotic drugs; hypertension (grade 2-3) in 35% (11/31) of patients; arrhythmias in 9% (3/31) of patients; dyspnea in 16% (5/31) of patients; fatigue in 32% (10/31) of patients. All patients were carefully monitored by expert cardiologists of our deparment.CONCLUSIONS: Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT.
Book Synopsis Multiple Myeloma and Other Plasma Cell Neoplasms by : Meletios A. Dimopoulos
Download or read book Multiple Myeloma and Other Plasma Cell Neoplasms written by Meletios A. Dimopoulos and published by Springer. This book was released on 2018-02-16 with total page 247 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.
Book Synopsis Hematopoietic Stem Cells V by : Lothar Kanz
Download or read book Hematopoietic Stem Cells V written by Lothar Kanz and published by . This book was released on 2005 with total page 264 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this volume, contributing scientists discuss the most recent developments in hematopoietic stem cell research and their clinical implications. The major topics covered are genetic and epigenetic regulation of stem cells, stem cell plasticity, stem cell regulation and self-renewal, embryonic stem cells as well as malignant stem cell biology. The field of hematopoietic stem cell biology is rapidly advancing, and new ideas and concepts supported by fascinating new technologies captivated the interest and excitement of the participants of the meeting. The sharing of new ideas and technologies with other scientists represents an invaluable stimulus, particularly for the young investigators in the field. It is hoped that the spirit of the meeting will be carried forward to the readers of this volume and that its content will stimulate new and fruitful projects in the field of stem cell biology.
Book Synopsis Oxford Handbook of Clinical Haematology by : Drew Provan
Download or read book Oxford Handbook of Clinical Haematology written by Drew Provan and published by Oxford University Press, USA. This book was released on 2009-02-19 with total page 881 pages. Available in PDF, EPUB and Kindle. Book excerpt: Providing essential information needed in clinical practice for the diagnosis and management of patients with blood disorders, this handbook covers haematological investigations and their interpretation, and commonly used protocols.
Book Synopsis Contemporary Bone Marrow Transplantation by : Mammen Chandy
Download or read book Contemporary Bone Marrow Transplantation written by Mammen Chandy and published by Springer. This book was released on 2021-03-25 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Bone Marrow transplantation or Hematopoietic stem cell transplantation is a life saving procedure in a number of diseases,hematological and non hematological, which fail alternative medical management or have no other treatment options. It has transformed the lives of thousands of patients and their families around the world battling with fatal or debilitating diseases.There are many unique aspects of bone marrow transplantation which makes it very different from solid organ transplants. There is an enormous amount of research going on in this field both at clinical and basic science levels.With the rapidly changing world and field of transplantation, there is a need for an authoritative and up to date resource for transplant professionals. This book titled Contemporary Bone Marrow Transplantation aims to be a reference text comprehensively covering various facets of hematopoietic stem cell transplants with latest insights about the technique and basic science behind it . The book is the product of collective effort of transplant professionals round the world, and will reflect their experience as well as the current standard of care practices in Stem cell transplantation.The book will be divided into different sections focusing on the basic science of bone marrow transplant, the technical aspects of the procedure itself and the supportive care of transplant patients.There will also be a section each on epidemiology, upcoming trends and also case studies , which will discuss real case scenarios from the experience of the authors, to illustrate the practical challenges in managing bone marrow transplant recipients.
